These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26254025)

  • 1. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
    Lin TH; Hu K; Flarakos J; Sharr-McMahon M; Mangold JB; He H; Wang Y
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):181-8. PubMed ID: 23680921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
    Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
    Chen N; Wen L; Lau H; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
    Darwish M; Nunez R; Youakim JM; Robertson P
    Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
    Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole.
    Yue Q; Mulder T; Rudewicz PJ; Solon E; Budha N; Ware JA; Lyssikatos J; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2013 Feb; 41(2):508-17. PubMed ID: 23223496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass balance, metabolic disposition, and pharmacokinetics of [
    Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
    Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
    Nijenhuis CM; Lucas L; Rosing H; Huitema ADR; Mergui-Roelvink M; Jamieson GC; Fox JA; Mould DR; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Aug; 35(4):478-490. PubMed ID: 28138829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
    Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
    Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Disposition, and Biotransformation of [
    Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
    Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.
    Wright LC; Maia J; Loureiro AI; Almeida L; Soares-Da-Silva P
    Drug Metab Lett; 2010 Aug; 4(3):149-62. PubMed ID: 20642448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.